Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

M. de Lima, R. E. Champlin, P. F. Thall, X. Wang, T. G. Martin, J. D. Cook, G. McCormick, M. Qazilbash, P. Kebriaei, D. Couriel, E. J. Shpall, I. Khouri, P. Anderlini, C. Hosing, K. W. Chan, B. S. Andersson, P. A. Patah, Z. Caldera, E. Jabbour, S. Giralt

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences